Don't Miss out on Research Tools:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Chromocell Therapeutics Corp ( (CHRO) ) has provided an announcement.
Chromocell Therapeutics Corporation has merged into its subsidiary, Channel Therapeutics Corporation, transitioning from Delaware to Nevada jurisdiction. This reincorporation means Channel Therapeutics now holds the assets, rights, and obligations of Chromocell and continues to be listed on NYSE American under the symbol ‘CHRO’. The move includes updates to indemnification agreements for directors and officers, reflecting Nevada laws, and may impact stockholder rights.
See more data about CHRO stock on TipRanks’ Stock Analysis page.
Trending Articles
- Boeing (NYSE:BA) Layoffs Expand, Start Hitting Multiple Factories
- Microsoft’s (NASDAQ:MSFT) New Computer is Exclusively a Cloud Machine
- Walmart (NYSE:WMT) Warns About Tariff-Driven Price Hikes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
